Viking Therapeutics VKTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $453.72M+31.5% | $344.96M+55.0% | $222.48M+43.2% | $155.32M+30.6% | $118.93M+17.0% | ||
| $48.28M-0.2% | $48.39M-7.6% | $52.36M-9.0% | $57.52M+7.7% | $53.39M+8.3% | ||
| $502M+27.6% | $393.34M+43.1% | $274.84M+29.1% | $212.84M+23.5% | $172.32M+14.2% | ||
| -$502M-27.6% | -$393.34M-43.1% | -$274.84M-29.1% | -$212.84M-23.5% | -$172.32M-14.2% | ||
| $29.64M-12.1% | $33.7M-10.2% | $37.51M-9.1% | $41.27M-6.3% | $44.06M+7.6% | ||
| $29.66M-12.0% | $33.7M-10.0% | $37.45M-9.3% | $41.29M-6.3% | $44.08M+7.6% | ||
| -$472.34M-31.3% | -$359.64M-51.5% | -$237.39M-38.4% | -$171.55M-33.8% | -$128.24M-16.6% | ||
| -$4.15-30.1% | -$3.19-50.5% | -$2.12-38.6% | -$1.53-33.0% | -$1.15-15.0% | ||
| -$502M-27.6% | -$393.34M-43.1% | -$274.84M-29.1% | -$212.84M-23.5% | -$172.32M-14.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's income statement data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.